{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:14:12Z","timestamp":1794856452583,"version":"4.9.1"},"reference-count":24,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,4,25]]},"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Due to long lag time between infection\/cancer diagnoses human papillomavirus (HPV) vaccination programs will deliver vaccine efficacy (VE) estimates against cancer end-points late. Cancer registry follow-up of population-based, randomised trial cohorts of vaccinated and unvaccinated women was undertaken for the estimation of VE against cervical intraepithelial neoplasia grade three and invasive cancer (CIN3+).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We report interim results with 98 561 person years of Finnish Cancer Registry -based follow-up of individually and\/or cluster randomised cohorts of HPV-16\/18 vaccinated and unvaccinated adolescent women enrolled in June 2003\/2005, and between May 2004 and April 2005, respectively. The cohorts comprised 15 627 18- to 19-year-old unvaccinated women (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01393470\">NCT01393470<\/jats:ext-link>\n                      ), and 2 401 and 64 16- to 17-year-old HPV-16\/18 vaccinated women participating the PATRICIA (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00122681\">NCT00122681<\/jats:ext-link>\n                      ) and HPV-012 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00169494\">NCT00169494<\/jats:ext-link>\n                      ) trials, respectively. The age-aligned passive follow-up started 6 months after the clinical trials\u2019 end.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the follow-up of 4.5 to 10 years post enrolment we identified 75 cases of cervical intraepithelial neoplasia grade 3 (CIN3) and 4 cases of invasive cervical cancer (ICC) in the unvaccinated cohort, and 4 CIN3 cases in the HPV-16\/18 vaccinated women. Diagnostic blocks were available for HPV typing from 87% of the cases. CIN3+ lesions were detectable in 54 cases. HPV16 was found in 26 of 50 unvaccinated CIN3+ cases, and in 3 CIN3+ cases in the HPV-16\/18 vaccinated women. The latter were all baseline positive for cervical HPV16 DNA. Baseline data was not available for the unvaccinated women. Intention-to-treat VE against any CIN3+ was 66% (95% CI 8, 88).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ten years post vaccination the AS04-adjuvanted HPV-16\/18 vaccine shows continued efficacy against CIN3+ irrespectively of HPV type. Vaccine efficacy was not observed in baseline HPV16 DNA positive subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT01393470.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-015867","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T20:10:20Z","timestamp":1503087020000},"page":"e015867","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":84,"title":["Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point\u2014registry-based follow-up of\n                    <i>three cohorts from randomized trials<\/i>"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct01393470","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00122681","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00169494","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00122681","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01393470","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Matti","family":"Lehtinen","sequence":"first","affiliation":[{"name":"University of Tampere, Tampere, Finland"},{"name":"Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Lagheden","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapio","family":"Luostarinen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Eriksson","sequence":"additional","affiliation":[{"name":"University of Tampere, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Apter","sequence":"additional","affiliation":[{"name":"VL-Medi, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Harjula","sequence":"additional","affiliation":[{"name":"University of Tampere, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjo","family":"Kuortti","sequence":"additional","affiliation":[{"name":"University of Tampere, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Natunen","sequence":"additional","affiliation":[{"name":"University of Tampere, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Palmroth","sequence":"additional","affiliation":[{"name":"University of Tampere, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Pet\u00e4j\u00e4","sequence":"additional","affiliation":[{"name":"University of Tampere, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Pukkala","sequence":"additional","affiliation":[{"name":"Finnish Cancer Registry, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Siitari-Mattila","sequence":"additional","affiliation":[{"name":"University of Tampere, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[{"name":"GSK Biologicals, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Nieminen","sequence":"additional","affiliation":[{"name":"University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorma","family":"Paavonen","sequence":"additional","affiliation":[{"name":"University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Dubin","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"key":"2025121221401784000_7.8.e015867.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.86"},{"key":"2025121221401784000_7.8.e015867.2","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1586\/erv.11.128","article-title":"HPV vaccines: what remains to be done?","volume":"10","author":"zur Hausen","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"2025121221401784000_7.8.e015867.3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp534"},{"key":"2025121221401784000_7.8.e015867.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70286-8"},{"key":"2025121221401784000_7.8.e015867.5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrclinonc.2013.84","article-title":"Clinical HPV vaccine trials and beyond","volume":"10","author":"Lehtinen","year":"2013","journal-title":"Nature Rev Clin Oncol"},{"key":"2025121221401784000_7.8.e015867.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044"},{"key":"2025121221401784000_7.8.e015867.7","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal Hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in Children","volume":"336","author":"Chang","year":"1997","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121221401784000_7.8.e015867.8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24442"},{"key":"2025121221401784000_7.8.e015867.9","doi-asserted-by":"publisher","DOI":"10.1258\/095646206776253453"},{"key":"2025121221401784000_7.8.e015867.10","doi-asserted-by":"publisher","DOI":"10.1258\/095646206778145550"},{"key":"2025121221401784000_7.8.e015867.11","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1016\/j.vaccine.2006.05.109","article-title":"Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries","volume":"24 Suppl 3","author":"Lehtinen","year":"2006","journal-title":"Vaccine"},{"key":"2025121221401784000_7.8.e015867.12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27971"},{"key":"2025121221401784000_7.8.e015867.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60946-5"},{"key":"2025121221401784000_7.8.e015867.14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1386-6532(00)00130-X","article-title":"Feasibility studies on HPV vaccination","volume":"19","author":"Paavonen","year":"2000","journal-title":"J Clin Virol"},{"key":"2025121221401784000_7.8.e015867.15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25887"},{"key":"2025121221401784000_7.8.e015867.16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/13625187.2010.536921","article-title":"Impact of HPV vaccination on quality of life","volume":"16","author":"Woodhall","year":"2011","journal-title":"Eur J Contracept Reproduct Health Care"},{"key":"2025121221401784000_7.8.e015867.17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/13625187.2013.801953","article-title":"Impact of HPV16\/18 vaccination on quality of life: a pilot study","volume":"18","author":"Eriksson","year":"2013","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"2025121221401784000_7.8.e015867.18","unstructured":"Kohdunkaulan, Ulkosynnytinten ja em\u00e4ttimen solumuutokset. Duodecim, 2010:1\u201332. www.kaypahoito.fi."},{"key":"2025121221401784000_7.8.e015867.19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcv.2016.04.016","article-title":"Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples","volume":"80","author":"Lagheden","year":"2016","journal-title":"J Clin Virol"},{"key":"2025121221401784000_7.8.e015867.20","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19961115)15:21<2379::AID-SIM457>3.0.CO;2-L"},{"key":"2025121221401784000_7.8.e015867.21","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980630)17:12<1403::AID-SIM834>3.0.CO;2-Y"},{"key":"2025121221401784000_7.8.e015867.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62218-7"},{"key":"2025121221401784000_7.8.e015867.23","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00591-14"},{"key":"2025121221401784000_7.8.e015867.24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV Faster: broadening the perspectives in the prevention of HPV related cancers","volume":"13","author":"Bosch","year":"2015","journal-title":"Nature Rev Clin Oncol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-015867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:40:26Z","timestamp":1765604426000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-015867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,18]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1136\/bmjopen-2017-015867"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-015867","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}